(Q38255999)

1 September 2017

1 reference

title

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus (English)

1 reference

Erratum to: Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 September 2017

1 reference

1 reference

ChEBI release 2020-05-28

ChEBI ID

82720

corrigendum / erratum

0 references

1

Lesley J Scott

1 reference

PubMed ID

25274537

1 September 2017

language of work or name

1 reference

1 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

74

1 reference

1 September 2017

15

1 reference

1 September 2017

1769-1784

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0298-1

1 September 2017

0 references

cites work

Diagnosis and classification of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Renal glucose reabsorption inhibitors to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Glycemic control and complications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Addressing cardiovascular risk in patients with type 2 diabetes: focus on primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0298-1

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers

21 January 2018

1 reference

12 December 2020

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes

1 reference

12 December 2020

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

1 reference

12 December 2020

Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects

1 reference

12 December 2020

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

1 reference

12 December 2020

SGLT-2 inhibitors and their potential in the treatment of diabetes

1 reference

12 December 2020

10.1007/S40265-014-0298-1

Identifiers

DOI

1 reference

PubMed ID

25274537

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25274537